Zulhasnimar v Dr Kuppu Velumani [2017] 5 MLJ 438: Reaffirming Bolam-Bolitho for Diagnosis and Treatment

Case at a glance

• Case name: Zulhasnimar bt Hasan Basri & Anor v Dr Kuppu Velumani P & Ors

• Citation: [2017] 5 MLJ 438

• Court: Federal Court of Malaysia

• Year: 2017

• Practice area: Medical Negligence

Background and facts

The plaintiff suffered serious injury during obstetric care provided by the defendants. The case turned on the standard of care expected of obstetricians in managing the delivery, and on whether the defendants had breached that standard.

After Foo Fio Na [2007] 1 MLJ 593, there was uncertainty in the lower courts about whether the patient-centric Whitaker test extended beyond risk disclosure to diagnosis and treatment, or whether Bolam-Bolitho still applied in those domains.

The issue before the court

The Federal Court was asked to clarify the boundary between Foo Fio Na (risk disclosure, Whitaker) and Bolam-Bolitho (diagnosis and treatment), and to articulate the modern Malaysian test for breach of duty in medical negligence.

Holding and reasoning

The Federal Court reaffirmed that for diagnosis and treatment, the Bolam test as modified by Bolitho remains the law. A doctor is not negligent if they acted in accordance with a practice accepted as proper by a responsible body of medical opinion — provided that opinion withstands logical analysis.

The patient-centric Whitaker test from Foo Fio Na is confined to the duty to inform and disclose risks. The two tests apply to different domains and are not in conflict.

Why this case still matters in 2026

The decision gave Malaysian doctors and litigators a clear, dual framework:

• Diagnosis & treatment → Bolam-Bolitho. Expert peer evidence is required, but the supporting opinion must withstand logical analysis.

• Disclosure of risks → Whitaker (per Foo Fio Na). What matters is what a reasonable patient would want to know.

For litigators, Zulhasnimar ended an era of confusion and clarified the framework now applied in every Malaysian med-neg trial.

Frequently asked questions

Does Zulhasnimar make Malaysian medical negligence harder or easier to prove?

It clarifies — neither harder nor easier. For risk disclosure (Foo Fio Na/Whitaker) the patient sets the standard, which favours claimants. For diagnosis and treatment (Bolam-Bolitho), peer evidence still drives the analysis but courts will reject opinions that lack logical basis.

What is the practical effect for hospitals in 2026?

Hospitals must continue to maintain robust clinical guidelines (for the Bolam-Bolitho standard) and clear consent practices (for the Foo Fio Na standard). Failure on either limb supports a negligence finding.

Is expert evidence still essential?

Yes. For diagnosis and treatment the case still depends on peer expert opinion. The difference post-Bolitho/Zulhasnimar is that the court is not bound to accept any peer opinion that lacks a logical basis.

Frequently asked questions

Does Zulhasnimar make Malaysian medical negligence harder or easier to prove?

It clarifies — neither harder nor easier. For risk disclosure (Foo Fio Na/Whitaker) the patient sets the standard, which favours claimants. For diagnosis and treatment (Bolam-Bolitho), peer evidence still drives the analysis but courts will reject opinions that lack logical basis.

What is the practical effect for hospitals in 2026?

Hospitals must continue to maintain robust clinical guidelines (for the Bolam-Bolitho standard) and clear consent practices (for the Foo Fio Na standard). Failure on either limb supports a negligence finding.

Is expert evidence still essential?

Yes. For diagnosis and treatment the case still depends on peer expert opinion. The difference post-Bolitho/Zulhasnimar is that the court is not bound to accept any peer opinion that lacks a logical basis.